Timothy West, MD
Neurology · Salt Lake City, UTNPI 1861650731
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $618,571 of the $856,461 with a category attached, or 72.2%. 40 manufacturers reported payments, led by Biogen at 47.0% of the total. Reporting peaked in 2019 at $218,948 and has fallen 56.4% since, to $95,452 in 2025. Among neurology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 927 payments — averaging $923.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$403K
- EMD Serono, Inc.$209K
- TG Therapeutics, Inc.$111K
- Novartis$56K
- Sanofi$42K
- Genentech USA, Inc.$17K
- plus $18K from 34 others
Across 4 payments — averaging $8136.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$33K
What the payments were for
- Consulting fees$153,17718%
- Speaking & faculty fees$618,57172%
- Travel & lodging$64,9608%
- Food & beverage$19,3192%
- Education$4330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$856,461 in reported general payments places this provider in the 95th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriflunomide | 23 | $1,539 |
| Gabapentin | 41 | $1,231 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $855 |
| Baclofen | 18 | $485 |
| Amitriptyline Hcl | 11 | $324 |
| Memantine Hcl | 15 | $146 |
| Zolpidem Tartrate | 18 | $34 |
Paid to pharmacies, not to this prescriber.
Other neurology in Salt Lake City
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
- Viktoria KaplanSalt Lake City$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.